ACCENTIA BIOPHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · FL · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | |
|---|---|---|---|
| Revenue | $4.1M | $4.0M | $5.4M |
| Operating income | −$11.5M | −$21.2M | −$3.6M |
| Net income | −$9.2M | −$15.7M | −$48.2M |
| Total assets | $2.6M | $5.9M | $5.0M |
| Total liabilities | $82.3M | $93.0M | $150.3M |
| Equity | −$63.1M | −$74.6M | −$122.2M |
| EPS (diluted) | — | — | — |
| Shares out. | 89.8M | 75.2M | 50.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- −284.6%
- Net margin
- −226.6%
- Return on equity
- 14.6%
- Return on assets
- −355.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 3185.7%
- Debt / equity
- —
- Book value / share
- $-0.70
- Revenue growth (YoY)
- 2.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Altman Z″ (distress)
- -596.99distress
- Accruals / assets
- −111.4%clean
- Beneish M-Score
- -8.74normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2013
- NT 10-Qmissed a reporting deadline ↗May 15, 2013
- NT 10-Kmissed a reporting deadline ↗Dec 29, 2008
- NT 10-Qmissed a reporting deadline ↗May 16, 2008
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Odonnell Francis E JrDirector | Nov 8, 2013 | J | 1.4M | $0.01 |
| Accentia Biopharmaceuticals Inc10% owner | Feb 22, 2013 | J | 4.8M | $0.12 |
| Odonnell Francis E JrOfficer — EXECUTIVE CHAIRMAN | Oct 24, 2012 | J | 500,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligation · Debt acceleration / triggering event · Director / officer change · Other material eventJul 15, 2013
- Director / officer change · Other material eventMar 7, 2013
- Director / officer changeFeb 22, 2013
- Debt acceleration / triggering eventNov 23, 2012
- Entered a material agreement · New financial obligation · Unregistered equity saleOct 15, 2012
- Regulation FD disclosure · Other material eventAug 14, 2012
- Entered a material agreement · Unregistered equity saleJun 21, 2012
- Entered a material agreement · New financial obligation · Unregistered equity saleJun 7, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- REVOKEDJan 15, 2016
- SC 13G/AAug 10, 2015
- SC 13GSCHEDULE 13GFeb 9, 2015
- 4PRIMARY DOCUMENTNov 12, 2013
- NT 10-QFOR PERIOD ENDED JUNE 30, 2013Aug 15, 2013
- 8-KJul 15, 2013
- NT 10-QFOR PERIOD ENDED MARCH 31, 2013May 15, 2013
- 8-KMar 7, 2013
- 4PRIMARY DOCUMENTFeb 22, 2013
- RWFeb 22, 2013
- 8-KFeb 22, 2013
- 10-QFOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2012Feb 14, 2013
- 10-KFORM 10-KDec 26, 2012
- 8-KFORM 8-KNov 23, 2012
- 4Oct 26, 2012
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.